Abstract
Background and purposeAdvancements in imaging and dose delivery enable boosting of the dominant intraprostatic lesions (DIL), while maintaining organs-at-risk (OAR) tolerances. This study aimed to assess the feasibility of DIL boosting for volumetric modulated arc therapy (VMAT), intensity modulated proton therapy (IMPT) and high dose rate brachytherapy (HDR-BT). Material and methodsDILs were defined on multiparametric magnetic resonance imaging and fused with planning CT for twelve patients. VMAT, IMPT and HDR-BT plans were created for each patient with an EQD2α/β DIL aimed at 111.6Gy, PTVinitialDpres was 80.9Gy (EBRT) with CTV D90%=81.9Gy (HDR-BT). Hard dose constraints were applied for OARs. ResultsHigher boost doses were achieved with IMPT compared to VMAT, keeping major OAR doses at similar levels. Patient averaged EQD2α/β D50% to DIL were 110.7, 114.2 and 150.1Gy(IsoE) for VMAT, IMPT and HDR-BT, respectively. Respective rectal wall Dmean were 30.5±5.0, 16.7±3.6, 9.5±2.5Gy(IsoE) and bladder wall Dmean were 21.0±5.5, 15.6±4.3 and 6.3±2.2Gy(IsoE). ConclusionsDIL boosting was found to be feasible with all investigated techniques. Although OAR doses were higher than for standard treatment approach, the risk levels were reasonably low. HDR-BT was superior to VMAT and IMPT, both in terms of OAR sparing and DIL boosting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
